Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Second Generation Dutasteride and Tamsulosin Combination
NCT02052713Phase 1Completed
- Sponsor
- GSK
- Start
- Feb 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dutasteride and tamsulosin in benign prostatic hyperplasia (BPH) (2 arms), sponsored by GSK. Primary endpoints: Pharmacokinetic profile of second generation dutasteride at 72 hours and Composite of PK parameters for tamsulosin HCl at 72 hours. Started Feb 2014; status: completed.
02
Drugs
dutasteridetamsulosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT02052713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02052713.